Home/Investors/Ally Bridge Group

Ally Bridge Group

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$6.1B

Focus Areas

4

Top Stage

Phase 3

Investment Focus

Urologic Oncology Bladder Cancer Autoimmune Diseases Inflammatory Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
CG Oncology	Phase 3	$6.1B	Urologic Oncology, Bladder Cancer
Sonoma Biotherapeutics	Phase 1	—	Autoimmune Diseases, Inflammatory Diseases

Frequent Co-Investors

Frazier Life Sciences1 shared ARCH Venture Partners1 shared Alexandria Venture Investments1 shared 8VC1 shared Vertex Ventures HC1 shared Lilly Asia Ventures1 shared Casdin Capital1 shared Decheng Capital1 shared